Fulcrum Therapeutics, Inc. Gains 45.96%

Fulcrum Therapeutics, Inc. (FULC:NASDAQ) shot up at $12.99, a gain of 46%. On Mon, Dec 08, 2025, FULC:NASDAQ touched a New 2-Week High of $12.99. The stock got featured on our News Catalysts scanner on Mon, Dec 08, 2025 at 05:50 PM in the 'PUBLIC OFFERING' category. From Mon, Nov 24, 2025, the stock recorded 33.33% Up Days and 40.00% Green Days

About Fulcrum Therapeutics, Inc. (FULC:NASDAQ)

Fulcrum Therapeutics Inc is a clinical-stage biopharmaceutical company. It has developed a proprietary product engine which employs to identify and validate cellular drug targets that can modulate gene expression. Its product candidate, losmapimod, is a small molecule that was developed for the treatment of FSHD, a muscle wasting disorder that leads to physical impairments and disability.